Bevacizumab for metastatic colon cancer: Does patient BMI influence survival?

Anti-Cancer Drugs

Volumn 26, Issue 3, 2015, Pages 363-366

  Kaidar Person, Orit ^a   Badarna, Hiba ^a   Bar Sela, Gil ^a  

^a RAMBAM MEDICAL CENTER   (Israel)

Author keywords

bevacizumab; BMI; colorectal cancer; diabetes; obesity

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ANTIANGIOGENIC THERAPY; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CANCER SURVIVOR; CLINICAL FEATURE; COLON CANCER; COMORBIDITY; DEMOGRAPHY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METASTATIC COLON CANCER; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TIME OF DEATH; CLINICAL TRIAL; COLONIC NEOPLASMS; DRUG EFFECTS; MORTALITY; MULTIVARIATE ANALYSIS; OBESITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SURVIVAL;

ADIPOSITY; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY MASS INDEX; COLONIC NEOPLASMS; COMORBIDITY; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84925486404     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000201     Document Type: Article

References (14)

1. Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr 2001; 131 (Suppl):3109S-3120S
2. Park HY, Kwon HM, Lim HJ, Hong BK, Lee JY, Park BE, et al. Potential role of leptin in angiogenesis: leptin induces endothelial cell proliferation and expression of matrix metalloproteinases in vivo and in vitro. Exp Mol Med 2001; 33:95-102
3. Vona-Davis L, Rose DP. Angiogenesis, adipokines and breast cancer. Cytokine Growth Factor Rev 2009; 20:193-201
4. Hausman GJ, Richardson RL. Adipose tissue angiogenesis. J Anim Sci 2004; 82:925-934
5. Slaughter KN, Thai T, Penaroza S, Benbrook DM, Thavathiru E, Ding K, et al. Measurements of adiposity as clinical biomarkers for first-line bevacizumabbased chemotherapy in epithelial ovarian cancer. Gynecol Oncol 2014; 133:11-15
6. Guiu B, Petit JM, Bonnetain F, Ladoire S, Guiu S, Cercueil JP, et al. Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer. Gut 2010; 59:341-347
7. Ladoire S, Bonnetain F, Gauthier M, Zanetta S, Petit JM, Guiu S, et al. Visceral fat area as a new independent predictive factor of survival in patients with metastatic renal cell carcinoma treated with antiangiogenic agents. Oncologist 2011; 16:71-81
8. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, HeimW, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-2342
9. Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausová J, Macarulla T, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012; 30:3499-3506
10. Grothey A, van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. CORRECT Study Group. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381:303-312
11. Faruk Aykan N, Yildiz I, Sen F, Kilic L, Keskin S, Ciftci R, et al. Effect of increased body mass index (BMI) on time to tumour progression (TTP) in unresectable metastatic colorectal cancer (mCRC) patients treated with bevacizumab-based therapy. Med Oncol 2013; 30:679
12. Griggs JJ, Mangu PB, Anderson H, Balaban EP, Dignam JJ, Hryniuk WM, et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2012; 30:1553-1561
13. Martin A, Komada MR, Sane DC. Abnormal angiogenesis in diabetes mellitus. Med Res Rev 2003; 23:117-145
14. Arevalo JF, Sanchez JG, Lasave AF, Wu L, Maia M, Bonafonte S, et al. Intravitreal bevacizumab (avastin) for diabetic retinopathy: the 2010 GLADAOF Lecture. J Ophthalmol 2011; 2011:584238